Milestone Scientific Reports Strong Growth in Q3 Revenue

Milestone Scientific Reports Impressive Revenue Growth for Q3

Addresses remarkable growth in international dental sales and ongoing expansion in pain management technology.

Milestone Scientific Inc. (NYSE: MLSS), a forefront player in the development of advanced computerized drug delivery systems for precise and pain-free injections, has delivered promising financial results for the recent quarter.

CEO Arjan Haverhals expressed satisfaction about a substantial 22% year-over-year growth in revenue, which reached $2.5 million for the third quarter. This increase was significantly bolstered by a robust performance in their dental segment, reporting an extraordinary 57% rise in international dental sales. The demand for their innovative dental products in both domestic and international markets has been pivotal in this expansion, showcasing the effectiveness of their e-commerce initiatives that facilitate effective outreach and product adoption.

The implementation of e-commerce has markedly improved how Milestone delivers its products, allowing them to sell directly to dental offices and groups. For instance, the STA Single Tooth Anesthesia System has seen positive traction among end users due to its convenient availability online. Remarkably, the revenue from U.S. e-commerce and dental services surged to approximately $1.2 million this quarter, further validating the company's strategic direction in enhancing customer accessibility.

Advancements in Medical Technologies

In addition to growth in the dental arena, Milestone is making strides in the medical field. Recently, they have gained Medicare Part B reimbursement for their CompuFlo® Epidural System, enhancing its positioning in the pain management sector. This advancement, in collaboration with First Coast Service Options Inc. and Novitas Solutions, marks a notable turning point. This system allows for real-time pressure-sensing epidural guidance, creating a safer and more efficient patient care scenario.

Strategic Partnerships and Collaborations

Milestone Scientific's partnership with Axial Biologics has amplified their distribution capabilities, allowing wider accessibility of the CompuFlo® Epidural System in crucial locations like New Jersey, Texas, and Florida. Notable clinics, such as Hudson Specialty Care and iHEAL Pain Center, have adopted this system, indicating growing enthusiasm from leading pain management centers. An encouraging sales pipeline is emerging alongside pilot programs that are gaining traction.

Financial Overview

As of the financial report, Milestone's revenue figures for the quarter were encouraging compared to the previous year, moving from $2.1 million to $2.5 million. This progress removes constraints of prior delays in freight-forwarding, which had impacted international sales in the last quarter. This quarter’s revenues also showed a substantial increment of approximately $0.5 million, indicating strong upward momentum.

Furthermore, the gross profit margin held steady at around 73%, demonstrating the benefits of the company's focused direct sales model, made notably efficient through their innovative online platform.

Future Prospects and Focus Areas

Milestone Scientific is committed to driving the expansion of the CompuFlo® Epidural System both nationally and internationally. The company is engaged in active discussions with various Medicare Administrative Contractors to extend their operational reach further, looking to secure more coverage across jurisdictions.

As of the end of the recent quarter, the company maintains a solid financial position with cash and cash equivalents totaling approximately $4.8 million, and working capital close to $6.9 million. This financial health underlies Milestone’s strategic endeavors and focus on ongoing innovations, ideally positioning them to shape advancements in patient care within the medical technology sector.

Conference Call Announcement

Milestone Scientific is set to host a conference call to discuss its Q3 financial results, as well as corporate progress and developments. Interested parties can join the call to gain deeper insights into the company’s strategies and future directions.

Frequently Asked Questions

What is Milestone Scientific known for?

Milestone Scientific Inc. specializes in computerized drug delivery systems for pain-free and precise injections, primarily in dental and medical applications.

How much revenue did Milestone Scientific report for Q3?

The company reported a total revenue of $2.5 million for the third quarter, reflecting a 22% year-over-year increase.

What factors contribute to Milestone's revenue growth?

Growth is driven by strong performance in international dental sales, implementation of e-commerce, and advancements in reimbursement for the CompuFlo® Epidural System.

What are the future plans for Milestone Scientific?

Milestone plans to expand the commercialization of the CompuFlo® Epidural System and further develop its e-commerce platform to enhance patient care and accessibility.

How can investors get in touch with Milestone Scientific?

Investors can reach out to Milestone Scientific's investor relations through Crescendo Communications via their contact email or phone number provided in corporate communications.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.